Human prostatic specific reductase

• US 5,786,204 A
• Filed: 06/05/1995
• Issued: 07/28/1998
• Est. Priority Date: 01/20/1995
• Status: Expired due to Fees

• Current Assignee: Human Genome Sciences Incorporated (GlaxoSmithKline PLC)
• Original Assignee: Human Genome Sciences Incorporated (GlaxoSmithKline PLC)
• Inventors: Rosen, Craig A., Meissner, Paul S., Hudson, Peter L., He, Wei W.
• Primary Examiner(s): Sisson, Bradley L.
• Application Number:
  US08/464,400
• Time in Patent Office: 1,149 Days
• Field of Search: 435/6, 434/94, 536/23.1, 536/23.5, 536/24.3, 536/24.31, 536/24.33, 536/25.3, 935/1, 935/2, 935/9, 935/10, 935/11, 935/19
• US Class Current: 435/252.3
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: C12N 9/0004 Oxidoreductases (1.)
• CPC Class Codes: G01N 2500/04 Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Abstract

A human prostatic specific reductase polypeptide and polynucleotides encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polynucleotides as a diagnostic marker for prostate cancer and as an agent to determine if the prostate cancer has metastasized. Also disclosed are antibodies specific to the prostatic specific reductase polypeptide which may be used to target prostate cancer cells and be used as part of a prostate cancer vaccine. Methods of screening for agonists and antagonists for the polypeptide and therapeutic uses of the antagonists are also disclosed.

Claims

1. An isolated polynucleotide comprising a polynucleotide sequence which is a member selected from the group consisting of:

(a) a polynucleotide sequence encoding a polypeptide comprising amino acid 2 to 316 of SEQ ID NO;

2; and

(b) the complement of (a).

2. The isolated polynucleotide of claim 1 wherein said member is (a).

3. A recombinant vector comprising the polynucleotide of claim 1, wherein said polynucleotide is DNA.

4. A recombinant host cell comprising the polynucleotide of claim 1, wherein said polynucleotide is DNA.

5. The isolated polynucleotide of claim 1 wherein said member is (a) and the polypeptide comprises amino acids 1 to 316 of SEQ ID No:

2.

6. The isolated polynucleotide of claim 1, wherein the polynucleotide is DNA.

7. The isolated polynucleotide of claim 1, wherein said polynucleotide is RNA.

8. The isolated polynucleotide of claim 1 comprising nucleotides 13 to 960 of SEQ ID NO:

1.

9. The isolated polynucleotide of claim 1 comprising nucleotides 10 to 960 of SEQ ID NO:

1.

10. The isolated polynucleotide of claim 1 having the polynucleotide sequence of SEQ ID NO:

1.

11. An isolated polynucleotide comprising a polynucleotide sequence which is a member selected from the group consisting of:

(a) a polynucleotide sequence encoding the same mature polypeptide encoded by the human cDNA in ATCC Deposit No. 75913; and

(b) the complement of (a).

12. The isolated polynucleotide of claim 11, wherein the member is (a).

13. The isolated polynucleotide of claim 11 comprising a polynucleotide encoding the same mature polypeptide encoded by the human cDNA in ATCC Deposit No. 75913.

14. An isolated polynucleotide comprising a polynucleotide sequence that will hybridize under stringent hybridization conditions with the full sequence of a member selected from the group consisting of:

(a) a polynucleotide sequence encoding amino acids 2 to 316 of SEQ ID NO;

2; and

(b) the complement of (a).

15. The polynucleotide according to claim 14, wherein said member is (b).

16. A recombinant vector comprising the polynucleotide of claim 15, wherein said polynucleotide is DNA.

17. A recombinant host cell comprising the polynucleotide of claim 15, wherein said polynucleotide is DNA.

18. An isolated polynucleotide comprising a polynucleotide sequence that will hybridize under stringent hybridization conditions with the full sequence of a member selected from the group consisting of:

(a) a polynucleotide sequence encoding the polypeptide encoded by the human cDNA in ATCC Deposit No. 75913; and

(b) the complement of (a).

19. The polynucleotide according to claim 18, wherein said member is (b).

20. A recombinant vector comprising the polynucleotide of claim 19, wherein said polynucleotide is DNA.

21. A recombinant host cell comprising the polynucleotide of claim 19, wherein said polynucleotide is DNA.